Lupin Ltd.
Fundamentals
- Market cap
- ₹1.07 lakh cr
- P/E
- 20.09×
- ROE
- 19.08%
- Debt / equity
- 0.30
- Div yield
- 0.76%
- 52-week range
- 1836.80 — 2494.00
Lupin Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 8 notes on Lupin Ltd.
July 2026
- 01 Jul 26 · 9:57 PM IST Brief Brief · Mega cap
Lupin's Somerset plant gets FDA's cleanest inspection verdict
US FDA issues EIR with VAI classification for Lupin's New Jersey facility after April inspection, confirming no objectionable conditions. Analyst says outcome is routine for the ₹1 lakh cr pharma major.
- 01 Jul 26 · 4:49 PM IST Brief Brief · Mega cap
Lupin wins wider European label for rare-disease drug NaMuscla
EMA approves NaMuscla for pediatric use and adds lower-dose capsules. The drug treats myotonia in a disease affecting only one in every 100,000 people, a niche win for a ₹1-lakh-cr pharma.
June 2026
- 17 Jun 26 · 5:09 PM IST Brief Brief · Mega cap
Lupin launches Azilsartan generic in US with 180-day exclusivity
First-to-file Azilsartan Medoxomil tablets hit the US market, but the $53.5M reference product adds less than 0.3% to Lupin's annual revenue.
- 08 Jun 26 · 12:20 PM IST Brief Brief · Mega cap
Lupin takes Luforbec to Spain, its third European market
The Indian drugmaker's inhaled respiratory product enters Spain via ERN, but the deal's financial terms are missing.
- 04 Jun 26 · 11:07 PM IST Brief Brief · Mega cap
Lupin lands sole US interchangeable biosimilar for Roche's Lucentis
The FDA approval for Ranluspec makes Lupin's product the only interchangeable ranibizumab biosimilar in the United States, a key regulatory distinction in the crowded eye-drug market.
- 03 Jun 26 · 11:05 AM IST Brief Brief · Mega cap
Lupin wins US FDA nod for generic Halaven, but the prize is tiny
The approval for Eribulin Mesylate Injection is a routine portfolio addition. The addressable US market is just $43.7 million.
May 2026
- 29 May 26 · 8:37 PM IST Brief Brief · Mega cap
Lupin lands six-month U.S. monopoly on colonoscopy drug Sutab
The company is the exclusive first-to-file generic, securing 180 days of protected sales in a $132.8M branded market.
- 22 May 26 · 3:54 PM IST Brief Brief · Mega cap
Lupin wins its first drug approval in China
The company cleared Oseltamivir Phosphate Oral Suspension for the Chinese market, marking a quiet start to its entry in the region.